Sionna Therapeutics (SION) Q1 2025 earnings summary

Executive summary

• Focused on developing novel medicines for cystic fibrosis (CF) by stabilizing the CFTR protein's NBD1 domain, aiming to restore near-normal function for CF patients.

• Completed interim dosing in Phase 1 trials for NBD1 stabilizers SION-719 and SION-451, both generally well tolerated; topline data expected Q2 2025.

• Preparing to initiate Phase 2a proof-of-concept and at least one dual combination MAD trial in H2 2025, with topline data for both anticipated mid-2026.

• Raised $199.6 million in net proceeds from an IPO in February 2025, with total cash, cash equivalents, and marketable securities of $354.7 million as of March 31, 2025, expected to fund operations into 2028.

• No revenue generated to date; accumulated deficit of $197.6 million as of March 31, 2025.

Financial highlights

• Net loss of $16.5 million for Q1 2025, compared to $11.8 million for Q1 2024.

• Research and development expenses increased to $13.7 million (up $3.4 million year-over-year), driven by expanded clinical programs and workforce.

• General and administrative expenses rose to $6.0 million (up $3.1 million year-over-year), mainly due to increased personnel and professional fees.

• Interest and other income totaled $3.2 million in Q1 2025, up from $1.3 million in Q1 2024, reflecting higher investment balances post-IPO.

• Cash, cash equivalents, and marketable securities totaled $354.7 million as of March 31, 2025.

Outlook and guidance

• Topline Phase 1 data for NBD1 stabilizers SION-719 and SION-451 expected in Q2 2025.

• Phase 2a proof-of-concept and dual combination MAD trials to begin in H2 2025, with topline data anticipated mid-2026.

• Existing cash, cash equivalents, and marketable securities expected to fund operations into 2028, based on current operating plans.

• Anticipates increased expenses as clinical development advances and as the company prepares for potential commercialization.